Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Antibody Treatment Slows Lung Cancer Growth in Mouse Model

By BiotechDaily International staff writers
Posted on 17 Mar 2014
Image: Space-filling model of the peptide hormone vasopressin (Photo courtesy of Wikimedia Commons).
Image: Space-filling model of the peptide hormone vasopressin (Photo courtesy of Wikimedia Commons).
A monoclonal antibody that specifically binds to the surface marker ProAVP (pro-vasopressin) impaired the growth of small-cell lung cancer tumors in a mouse model.

Investigators at Dartmouth College (Hanover, NH, USA) previously had demonstrated that human small-cell lung cancer (SCLC) seemed to universally express the vasopressin gene, and this led to the presence of a cell surface marker representing the entire pro-hormone precursor.

Vasopressin, which is derived from a pro-hormone precursor that is synthesized in the hypothalamus and stored in vesicles at the posterior pituitary, is a peptide hormone that controls the reabsorption of molecules in the tubules of the kidneys by affecting the tissue's permeability. It also increases peripheral vascular resistance, which in turn increases arterial blood pressure. It plays a key role in homeostasis, by the regulation of water, glucose, and salts in the blood.

The investigators treated a group of SCLC mice with MAG-1, a mouse monoclonal antibody specific for the pro-vasopressin C-terminal moiety. They reported in the February 14, 2014, online edition of the journal Frontiers in Oncology that the antibody attached to SCLC cells and it was internalized. Antibody treatment decreased the rate of increase in tumor size by half, and doubling time by about three-fold. Normal tissues seemed not to be affected.

"We are developing methods of antibody-targeted treatment for recurrent small-cell lung cancer," said senior author Dr. William G. North, professor of physiology at Dartmouth College. "Targeting with a humanized MAG-1 can likely be effective, especially when given in combination with chemotherapy, for treating a deadly disease for which there is no effective therapy."

Related Links:

Dartmouth College



RANDOX LABORATORIES
BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.